本帖最后由 老马 于 2013-3-13 13:43 编辑 X7 y( _) T9 I* G% r
, l/ S3 O& p4 L健择（吉西他滨）+顺铂+阿瓦斯汀
" }1 P* c- O5 o0 k6 i Gemzar +Cisplatin + Avastin, n% ]+ d2 \- s% s; u
http://annonc.oxfordjournals.org/content/21/9/1804.full
$ C6 I$ u0 K+ i1 a! A; lOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
4 v6 S7 O( { e8 U5 Q7 gPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. 6 m3 A0 Y# U+ G8 n7 ]8 L
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
0 d8 s: Y& b1 z3 \; s+ g9 e
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 945)
. j" @2 z3 s2 D5 v华为网盘附件： z9 V# r, Y2 B$ ]- N
【华为网盘】ava.JPG
, k) p9 \ t$ |$ o |
显身卡
